RCM Automation Investment and Benefit Attribution Adviser

The mandate

The investment committee's standing question is whether proposed RCM automation produces financially attributable benefit or merely changes where work is performed. The adviser will challenge the investment and benefit logic. The remit does not approve clinical processes, select technology or assume that reduced task time automatically becomes cash or contribution.

Four reserved days monthly cover benefit evidence, a sponsor challenge and investment committee attendance. The meeting is included. A benefit question receives acknowledgement within two working days and a documented financial view within four after the necessary capacity and cost records are supplied. Continuous implementation advice is outside the retainer.

The nine-month term begins on 19 October 2026. The investment chair may renew where independent attribution challenge remains useful to the next automation choices. No line authority over delivery or technology teams is granted, and the adviser carries no executive responsibility for implementation. Finance and operating leaders retain benefit approval, deployment and service obligations.

The sponsor supplies authorised business cases, workload and capacity baselines, implementation costs and benefit tracking. Advice must distinguish theoretical effort reduction, released capacity, redeployed work and actual financial value. Where an automation benefit depends on demand absorbing capacity or a staffing decision outside the case, that dependency should remain explicit.

Concurrent non-competing advice is allowed. Vendor remuneration, participation in the same implementation or a competing service-provider retainer may create a conflict and requires disclosure or recusal. Technology procurement, workforce execution and clinical or regulatory certification are excluded. The committee is buying independent financial challenge, not a favourable savings endorsement or an additional programme manager.

What you will own

• Challenge benefit claims by tracing task efficiency through capacity and contribution, pressing sponsors to identify the operating decision needed before time saved becomes financial value.
• Test baselines for workload, complexity and demand differences, advising where an apparent improvement reflects a changed case mix rather than automation impact.
• Shape staged investment options around attributable evidence, distinguishing a useful pilot from a scale commitment whose benefits remain dependent on unapproved staffing assumptions.
• Examine implementation and continuing support costs alongside benefits, identifying where a narrow efficiency measure omits the total economic burden of the intervention.
• Press owners to retain redeployment and absorption assumptions, preventing released capacity from being counted simultaneously as cost reduction and additional revenue.
• Review closure evidence for realised benefit and remaining prerequisites, advising what can be claimed now and what must stay a conditional future outcome.
• Record independent recommendations and conflict limitations in an attribution note, leaving deployment, workforce decisions and all financial approvals with authorised executives.

Candidate qualifications

• Evidence senior business-finance or FP&A judgement involving service automation. Explain a benefit claim you challenged, the operating dependency identified and how the investment recommendation changed.
• Demonstrate attribution analysis that separates task efficiency, capacity and cash. Candidates should describe a case where time saved did not become economic value and show the evidence used to explain the difference.
• Provide an investment review that considered workload and complexity shifts. Explain how a misleading before-and-after comparison was corrected and what uncertainty remained.
• Show independence from vendors and implementation incentives. Describe a conflict, recusal or opinion that resisted premature savings endorsement, keeping advice separate from deployment and workforce decisions.
• Demonstrate a sustainable four-day monthly review rhythm that turns RCM capacity evidence into a usable financial benefit opinion. The role requires demonstrated finance scope, not clinical or technology approval. Candidates should explain how a redeployment assumption remained visible, what evidence would justify stronger benefit confidence and why the same released capacity could not be claimed twice across cost and growth cases. Show how the benefit note handles capacity that is released but cannot yet be absorbed by demand. Explain the conditional financial value, the owner of the next operating decision and the evidence required before the committee can count an actual contribution or cash improvement.

Application

Applications for this mandate are received in one way only: through the India Board Terminal's application process. It is automated end to end. Your Executive Passport travels to the mandate holder in its confidential form, your answers to the three questions below are read before anything else in your file, and every stage that follows is recorded on your applications page.

There is no address to write to and no intermediary to call. The mandate holder reads what the Terminal delivers and nothing else, which is what keeps the process the same for every applicant and keeps your name out of it until you release it. Applications close on 14 October 2026. Mandate reference PCT-ADV-2026-IND-19.